3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Brain Neoplasms
13
Glioblastoma
7
Glioma
6
Meningioma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Oligodendroglioma
2
Neuroblastoma
2
Neoplasms
2
Medulloblastoma
2
Ependymoma
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Spinal Cord Neoplasms
1
Recurrence
1
Neurofibromatosis 1
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Diseases
1
Astrocytoma
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Drug Therapy
3
Antilymphocyte Serum
3
verubulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
abemaciclib
×
CNS
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled